Skip to main content
Fig. 3 | BMC Infectious Diseases

Fig. 3

From: Assessing the impact of pneumococcal conjugate vaccines on invasive pneumococcal disease using polymerase chain reaction-based surveillance: an experience from South Africa

Fig. 3

Rates of invasive S. pneumoniae-associated hospitalizations among HIV-uninfected children <2 years of age at Chris-Hani Baragwanath Academic Hospital, Soweto, South Africa, 2009–2012. a: lytA-positive cases (SARI program) (7-valent pneumococcal conjugate vaccine (PCV-7) serotypes/serogroups included: 4, 6A/B, 9A/V/L/N, 14, 18A/B/C, 19B/F, 23 F; additional 13-valent pneumococcal conjugate vaccine (PCV-13) serotypes/serogroups included: 1, 3, 5, 7A/F, 19A). b: culture-positive cases (GERMS program) (7-valent pneumococcal conjugate vaccine (PCV-7) serotypes included: 4, 6A/B, 9 V, 14, 18C, 19 F, 23 F; additional 13-valent pneumococcal conjugate vaccine (PCV-13) serotypes included: 1, 3, 5, 7 F, 19A). Non-vaccine serotypes included serotypes/serogroups not included in PCV-7 or PCV-13, including samples that tested negative for the 42 serotypes detected by the serotyping assay for lytA-positive samples

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us